These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9218581

  • 1. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.
    Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE.
    J Immunol; 1997 Jul 15; 159(2):664-73. PubMed ID: 9218581
    [Abstract] [Full Text] [Related]

  • 2. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 3. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H, Chang AE, Shu SY.
    Cancer Res; 1992 Mar 01; 52(5):1129-36. PubMed ID: 1531321
    [Abstract] [Full Text] [Related]

  • 4. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE.
    Cancer Res; 2003 May 15; 63(10):2546-52. PubMed ID: 12750278
    [Abstract] [Full Text] [Related]

  • 5. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ.
    J Immunol; 1998 Jan 01; 160(1):334-44. PubMed ID: 9551989
    [Abstract] [Full Text] [Related]

  • 6. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE.
    Cancer Res; 2005 Feb 01; 65(3):1063-70. PubMed ID: 15705908
    [Abstract] [Full Text] [Related]

  • 7. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 8. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A, Aruga E, Cameron MJ, Chang AE.
    J Leukoc Biol; 1997 Apr 15; 61(4):507-16. PubMed ID: 9103238
    [Abstract] [Full Text] [Related]

  • 9. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK.
    J Immunol; 2009 Apr 01; 182(7):4217-25. PubMed ID: 19299720
    [Abstract] [Full Text] [Related]

  • 10. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.
    Otolaryngol Head Neck Surg; 2001 Apr 01; 124(4):436-41. PubMed ID: 11283503
    [Abstract] [Full Text] [Related]

  • 11. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW, Chang AE.
    Cancer Gene Ther; 1997 Apr 01; 4(3):157-66. PubMed ID: 9171934
    [Abstract] [Full Text] [Related]

  • 12. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 13. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 14. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z, Tang C, Xu S, Zhang B, Zhang X, Moyana T, Yang J, Xiang J.
    Cell Mol Immunol; 2007 Aug 15; 4(4):277-85. PubMed ID: 17764618
    [Abstract] [Full Text] [Related]

  • 15. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1994 May 15; 54(10):2744-50. PubMed ID: 8168105
    [Abstract] [Full Text] [Related]

  • 16. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
    Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP.
    J Immunol; 1999 Aug 15; 163(4):1923-8. PubMed ID: 10438927
    [Abstract] [Full Text] [Related]

  • 17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 18. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
    Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abdulsamad K, Adams SL.
    Immunol Invest; 2008 Nov 01; 37(4):315-38. PubMed ID: 18569073
    [Abstract] [Full Text] [Related]

  • 19. CDR3 spectratyping identifies clonal expansion within T-cell subpopulations that demonstrate therapeutic antitumor activity.
    Kim JA, Rao P, Graor H, Rothchild K, O'keefe C, Maciejewski JP.
    Surgery; 2004 Aug 01; 136(2):295-302. PubMed ID: 15300194
    [Abstract] [Full Text] [Related]

  • 20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 01; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.